PACE Stages 2 and 3 will provide the only world-class commercial and research laboratory space offered to the private sector within Australia’s Biotechnology Heart.
These two stages will comprise up to 60,000 sqm of space for offices, research laboratories and meeting facilities and can be purpose-built to individual business specifications. Find out more.
Pharmacy and biotechnology businesses located at PACE reap major competitive advantages through engagement with The University of Queensland’s world-leading research teams, its highly successful commercialisation and intellectual property enterprises, and its success in bringing products to market.
UQ is nationally and internationally recognised as not only a research powerhouse, but one which also has the talent and commercial know-how to bring products to market.
Through PACE, UQ can actively help industry to establish collaborative relationships with its embedded research teams across the Princess Alexandra Hospital, Diamantina Institute, Translational Research Institute, the Institute of Molecular Bioscience and the University’s other high performing research centres.
Being on-site at PACE will also allow businesses to leverage relationships with other occupants of the surrounding biotechnology community in ways which are simply not possible from other locations.
Scientists know that new research directions, partnerships and even “eureka” moments often occur in less formal situations. The PACE design provides the perfect incubator environment for this by featuring:
|
- Unique shared spaces and infrastructure – lecture rooms, meeting rooms and eating spaces, enabling industry partners to have unparalleled access to researchers at the cutting edge of pharmaceutical innovations
- Industry partners as active participants in seminars and workshops
- UQ-led high level discussions across the site with leading researchers and educationalists
- On-site, real time access to expertise in crucial areas for drug development, such as dosage form design and basic drug discovery, through to pharmacokinetics and pharmacodynamics, pre-clinical studies, modelling and simulation for clinical studies, pharmacoeconomics, pharmacoepidemiology and clinical trial design, through to health service evaluation and post-marketing surveillance.
Co-location will lead to a faster path to market by enabling advanced level discussions with world leaders at formal and informal levels.
PACE will encompass every activity within the development pipeline, from discovery to product development, testing and trialing, to commercialisation and marketing.
PACE is the breakthrough zone which will underpin the next generation of achievements in pharmaceutical science and a faster path to market for new drug therapies.
For information about facilities or options for industry, contact:
David Goodchild, Alba Capital Partners
PACE Precinct Director
T: 07 3231 8020
E: dgoodchild@albacapital.com.au
M: 0419 795 077
|
